[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 14 of about 14
1. Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D, Ralston SH: Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther; 2009 Aug;8(8):2339-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo.
  • Previous studies have shown that genetic inactivation of IkappaB kinase (IKK), a key component of NF-kappaB signaling, inhibits osteoclastogenesis, but the effects of pharmacologic IKK inhibitors on osteolytic bone metastasis are unknown.
  • In conclusion, pharmacologic inhibitors of IKK are effective in preventing osteolytic bone metastasis in this model and might represent a promising class of agents to the prevention and treatment of metastatic bone disease associated with breast cancer.
  • [MeSH-minor] Animals. Apoptosis. Bone Resorption / metabolism. Bone Resorption / pathology. Cell Movement / drug effects. Female. Humans. Male. Osteoclasts / drug effects. Osteoclasts / pathology. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671767.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.11.10 / I-kappa B Kinase
  •  go-up   go-down


2. Kurth AA, Müller R: The effect of an osteolytic tumor on the three-dimensional trabecular bone morphology in an animal model. Skeletal Radiol; 2001 Feb;30(2):94-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN AND MATERIALS: Walker carcinosarcoma 256 malignant breast cancer cells (W256) were surgically implanted into the medullary canal of the left femur of 15 4-month-old rats.
  • Twenty-eight days after surgery all animals were killed and both femora from each rat were harvested.
  • Recent advances in therapeutic approaches for skeletal diseases such as osteoporosis and metastatic bone diseasse rely on an understanding of the effects of the agents on the mechanical properties of bone.
  • [MeSH-minor] Animals. Bone Density. Carcinoma 256, Walker. Female. Femur / pathology. Femur / radiography. Microradiography. Neoplasm Transplantation. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11310206.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


3. Clemons M, Kelly J, Watson AJ, Howell A, McElhinney RS, McMurry TB, Margison GP: O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. Br J Cancer; 2005 Nov 14;93(10):1152-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
  • Tumour resistance to chemotherapy involving methylating agents such as DTIC (dacarbazine) and temozolomide is linked to expression of the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (MGMT).
  • We have examined the effect of the modified guanine base, O(6)-(4-bromothenyl)guanine (PaTrin-2, Patrin, Lomeguatrib) on MGMT activity and cell or xenograft tumour growth inhibition by temozolomide in the human breast carcinosarcoma cell line, MCF-7.
  • A PaTrin-2-temozolomide combination may therefore be beneficial in the treatment of human breast cancers.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Dacarbazine / analogs & derivatives. Drug Resistance, Neoplasm / drug effects. Guanine / analogs & derivatives
  • [MeSH-minor] Animals. Body Weight / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Humans. Male. Mice. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. GUANINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 2003;21(6):821-9 [14735685.001]
  • [Cites] Carcinogenesis. 2003 Apr;24(4):625-35 [12727789.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):296-307 [15057289.001]
  • [Cites] Cancer Res. 1987 Feb 15;47(4):936-42 [3802100.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6119-29 [2205376.001]
  • [Cites] Cancer Biochem Biophys. 1991 Jun;12(1):53-8 [1769005.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):256-60 [1531148.001]
  • [Cites] Carcinogenesis. 1992 Sep;13(9):1503-7 [1394831.001]
  • [Cites] Br J Cancer. 1993 Feb;67(2):216-21 [8431354.001]
  • [Cites] Semin Oncol. 1994 Aug;21(4 Suppl 7):25-31 [7916487.001]
  • [Cites] Cancer Invest. 1994;12(6):605-10 [7994595.001]
  • [Cites] Exp Hematol. 1995 Feb;23(2):112-6 [7828668.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Mar 17;208(2):688-96 [7695624.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1566-73 [9057638.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(3):266-72 [9219512.001]
  • [Cites] Eur J Cancer. 1997 Nov;33(13):2171-82 [9470803.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1129-34 [9816278.001]
  • [Cites] J Med Chem. 1998 Dec 17;41(26):5265-71 [9857094.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):837-47 [9815757.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2402-10 [10344750.001]
  • [Cites] Int J Cancer. 2000 Jan 15;85(2):248-52 [10629085.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):966-70 [10741722.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(6):509-12 [10854140.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3025-31 [10955780.001]
  • [Cites] Methods Mol Biol. 2000;152:49-61 [10957968.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3522-8 [11032594.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):69-74 [11249051.001]
  • [Cites] Biochim Biophys Acta. 2001 Mar 21;1471(3):M89-98 [11250065.001]
  • [Cites] Bioessays. 2002 Mar;24(3):255-66 [11891762.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2388-99 [11981013.001]
  • [Cites] Br J Cancer. 2002 Jun 5;86(11):1797-802 [12087469.001]
  • [Cites] Int J Cancer. 2002 Aug 10;100(5):615-7 [12124813.001]
  • [Cites] Mutagenesis. 2002 Nov;17(6):483-7 [12435845.001]
  • [Cites] Int J Cancer. 2003 Feb 20;103(5):686-92 [12494480.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):37-44 [12517538.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1645-56 [15014015.001]
  • (PMID = 16278661.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / O(6)-(4-bromothenyl)guanine; 5Z93L87A1R / Guanine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  • [Other-IDs] NLM/ PMC2361498
  •  go-up   go-down


Advertisement
4. Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, Cailleux PE, Lhomme C: Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer; 2002 Sep-Oct;12(5):496-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their median age at the diagnosis of breast cancer was 58 years (41-68), and 69 years (50-84) at the diagnosis of uterine carcinosarcoma.
  • The median length of exposure to tamoxifen was 9 years (5-20), and the median time from the initiation of tamoxifen to the diagnosis of the uterine malignancy (latency period) 9 years (7-20).
  • All patients presented with an advanced stage (IIA-IVA).
  • Our data, together with those of the literature, plead for a causal role of a prolonged exposure to tamoxifen on the subsequent development of uterine carcinosarcoma.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Carcinosarcoma / chemically induced. Carcinosarcoma / pathology. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / diagnosis. Breast Neoplasms / drug therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Incidence. Long-Term Care. Middle Aged. Risk Assessment. Survival Rate

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Cancer. 2004 Mar-Apr;14(2):395 [15086746.001]
  • [CommentIn] Int J Gynecol Cancer. 2003 Sep-Oct;13(5):697-8; author reply 697-8 [14675359.001]
  • (PMID = 12366669.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 27
  •  go-up   go-down


5. Leung F, Terzibachian JJ, Govyadovskiy A, Bourtembourg A, Maillet R, Riethmuller D: [Tamoxifen in the adjuvant setting for breast cancer: Reflexions about the risk of uterine carcinosarcoma]. Gynecol Obstet Fertil; 2009 May;37(5):447-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tamoxifen in the adjuvant setting for breast cancer: Reflexions about the risk of uterine carcinosarcoma].
  • [Transliterated title] Traitement adjuvant du cancer du sein par le tamoxifène : réflexions sur le risque de carcinosarcome utérin.
  • The role of aromatase inhibitors as alternative to tamoxifen therapy in the adjuvant setting of breast cancer is discussed.
  • The eventual implications of the presumed association of uterine carcinosarcoma and tamoxifen therapy on the choice of the therapeutic agent in the adjuvant setting of hormone-sensitive breast cancer are discussed.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Carcinosarcoma / drug therapy. Tamoxifen / therapeutic use. Uterine Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394886.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Estrogen Antagonists; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


6. Leung F, Terzibachian JJ, Govyadovskiy A, Bourtembourg A, Aouar Z, Fat BC, Maillet R, Riethmuller D: [Uterine carcinosarcomas associated with tamoxifen therapy. Report of two cases and review of the literature]. J Gynecol Obstet Biol Reprod (Paris); 2009 Apr;38(2):173-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carcinosarcomes utérins associés au traitement par le tamoxifène. A propos de deux cas et revue de la littérature.
  • Although these tumours usually arise de novo, some cases developed under tamoxifen therapy have been reported.
  • We report two more cases of uterine carcinosarcoma occurring in two postmenopausal patients benefiting from tamoxifen therapy as adjuvant treatment of breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Carcinosarcoma / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Female. Humans

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135318.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 38
  •  go-up   go-down


7. Hennessy BT, Giordano S, Broglio K, Duan Z, Trent J, Buchholz TA, Babiera G, Hortobagyi GN, Valero V: Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol; 2006 Apr;17(4):605-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphasic metaplastic sarcomatoid carcinoma of the breast.
  • BACKGROUND: Breast biphasic metaplastic sarcomatoid carcinoma (MSC) is rare and aggressive.
  • Anderson Cancer Center (MDACC) with 213 MSC and 98 carcinosarcoma patients identified through the Surveillance, Epidemiology and End-Results (SEER) database to describe clinical and pathologic characteristics.
  • PATIENTS AND METHODS: We searched the MDACC (1985-2001) and SEER databases (1988-2001) for breast MSC and carcinosarcoma patients.
  • CONCLUSIONS: Breast MSC and carcinosarcoma are aggressive, treatment-refractory tumors with shared clinical features and outcome similar to poorly differentiated receptor-negative adenocarcinomas.
  • New therapeutic agents are needed.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16469754.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Dubin M, Fernandez Villamil SH, Stoppani AO: [Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use]. Medicina (B Aires); 2001;61(3):343-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Citotoxicidad de la beta-lapachona: una o-naftoquinona con posibles usos terapéuticos.
  • Initial observations proved its capability for inhibiting growth of Yoshida tumor and Walker 256 carcinosarcoma. beta-Lap redox-cycling in the presence of reductants and oxygen yields "reactive oxygen species" (ROS: O2-, OH and H2O2) which cytotoxicity led to assume its role in beta-lap activity in cells. beta-Lap inhibited DNA synthesis in Trypanosoma cruzi as well as topoisomerases I and II, poly(ADP-ribose) polymerase (PARP) in different cells.
  • These enzymes are essential for maintaining DNA structure. beta-Lap inhibited growth of a large variety of tumor cells including epidermoid laringeal cancer, prostate, colon, ovary and breast cancer and also different types of leukemia cells.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Apoptosis / drug effects. Naphthoquinones / pharmacology. Neoplasms / drug therapy. Poly(ADP-ribose) Polymerases / metabolism. Reactive Oxygen Species / physiology
  • [MeSH-minor] Animals. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / enzymology. Humans. Sarcoma, Yoshida / drug therapy. Sarcoma, Yoshida / enzymology. Topoisomerase I Inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11474885.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Naphthoquinones; 0 / Reactive Oxygen Species; 0 / Topoisomerase I Inhibitors; 4707-32-8 / beta-lapachone; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  • [Number-of-references] 58
  •  go-up   go-down


9. Raspollini MR, Mecacci F, Paglierani M, Marchionni M, Taddei GL: HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. Pathol Res Pract; 2005;201(2):141-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy.
  • HER-2/neu is an oncogene located on chromosome 17, encoding a type 1 tyrosine kinase growth factor receptor.
  • HER-2/neu is overexpressed in 25-30% of breast cancers, increasing the aggressiveness of the tumor.
  • We describe HER-2/neu overexpression and her-2/neu oncogene amplification in a case of uterine carcinosarcoma occurring in a 46-year-old women who had undergone mastectomy and a 2-year postoperative treatment with tamoxifen for invasive breast cancer.
  • This is the first study demonstrating HER-2/neu expression and her-2/neu oncogene amplification in a uterine carcinosarcoma that has developed in a patient given tamoxifen therapy.
  • It still needs to be clarified whether HER-2/neu overexpression increases the aggressiveness of carcinosarcoma, or whether HER-2/neu has a direct role in its pathogenesis, as described in breast cancers.
  • Our observation of the her-2/neu oncogene amplification does not shed light on the prognostic impact of uterine carcinosarcoma following tamoxifen therapy, but it may indicate the need for further studies of HER-2/neu overexpression in a larger series of uterine carcinosarcoma patients, and it may permit us to hypothesize about a therapeutic concept, including the inhibition of HER-2/neu by humanized monoclonal antibodies also in uterine carcinosarcoma patients.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Carcinosarcoma / genetics. Genes, erbB-2. Neoplasms, Second Primary / genetics. Tamoxifen / adverse effects. Uterine Neoplasms / genetics
  • [MeSH-minor] Breast Neoplasms / drug therapy. Female. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15901136.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


10. Turbiner J, Moreno-Bueno G, Dahiya S, Sánchez-Estevez C, Hardisson D, Prat J, Oliva E, Palacios J: Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen. Mod Pathol; 2008 Aug;21(8):925-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Use of tamoxifen for treatment and prevention of breast cancer is becoming increasingly common.
  • In the random control group, there were 26 endometrioid endometrial carcinomas and one carcinosarcoma.
  • In conclusion, there was a direct relationship between tamoxifen exposure and overexpression of beta-catenin oncoprotein, which is known to play a major role in the pathogenesis of estrogen-driven, type I endometrial adenocarcinoma.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Endometrial Neoplasms / chemically induced. Endometrial Neoplasms / pathology. Tamoxifen / adverse effects
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / chemically induced. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Microsatellite Instability. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Neoplasm Staging. PTEN Phosphohydrolase / genetics. PTEN Phosphohydrolase / metabolism. Proto-Oncogene Proteins p21(ras) / genetics. Proto-Oncogene Proteins p21(ras) / metabolism. Survival Rate. beta Catenin / genetics. beta Catenin / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500270.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Neoplasm Proteins; 0 / beta Catenin; 094ZI81Y45 / Tamoxifen; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


11. Fotiou S, Hatjieleftheriou G, Kyrousis G, Kokka F, Apostolikas N: Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: two case-reports and review of the literature. Anticancer Res; 2000 May-Jun;20(3B):2015-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: two case-reports and review of the literature.
  • Two cases of uterine carcinosarcoma developing after long-term tamoxifen (TAM) treatment are presented.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Carcinosarcoma / chemically induced. Mixed Tumor, Mullerian / chemically induced. Neoplasms, Second Primary / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / surgery. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Mastectomy. Methotrexate / administration & dosage. Ovariectomy. Peritoneal Neoplasms / secondary. Polyps / chemically induced

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10928144.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF regimen
  • [Number-of-references] 42
  •  go-up   go-down


12. Lavie O, Longacre T, Segev Y, Husain A: Ovarian carcinosarcomas associated with prolonged use of tamoxifen: case reports. Int J Gynecol Cancer; 2009 Dec;19(9):1521-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: We present 2 cases of ovarian carcinosarcomas in patients with a personal history of breast carcinoma who were treated for a prolonged period with tamoxifen.
  • CONCLUSIONS: To our knowledge, these 2 cases are the first to describe the possible association between ovarian carcinosarcomas and previous personal and familial history of breast carcinoma andor prolonged use of tamoxifen.
  • [MeSH-major] Carcinosarcoma / chemically induced. Ovarian Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Aged. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Carcinoma / drug therapy. Female. Humans. Middle Aged. Neoplasms, Second Primary / chemically induced. Time Factors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955929.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


13. Fles R, Hoogendoorn WE, Platteel I, Scheerman CE, de Leeuw-Mantel G, Mourits MJ, Hollema H, van Leeuwen FE, van Boven HH, Nederlof PM: Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure. Genes Chromosomes Cancer; 2010 Aug;49(8):699-710
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tamoxifen has been a very effective treatment for breast cancer for several decades, however, at the same time increases the risk of endometrial cancer, especially after prolonged exposure.
  • We investigated whether endometrial tumors, which developed after prolonged tamoxifen treatment for breast cancer, are genetically different from endometrial tumors without preceding tamoxifen exposure.
  • We compared the genomic profiles of 52 endometrial tumors from breast cancer patients after long-term (>or=2 years) tamoxifen use (endometrioid adenocarcinomas, n = 26; carcinosarcomas, n = 14; and serous adenocarcinomas, n = 12) with endometrial tumors from unexposed breast cancer patients (n = 45).
  • Tumors with many genomic aberrations were in general ER-negative.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / genetics. Endometrial Neoplasms / genetics. Gene Expression Profiling. Neoplasms, Second Primary. Tamoxifen / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinosarcoma / drug therapy. Carcinosarcoma / genetics. Carcinosarcoma / pathology. Case-Control Studies. Chromosome Aberrations. Comparative Genomic Hybridization. Female. Humans. Immunoenzyme Techniques. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20544844.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


14. Zafrakas M, Kostopoulou E, Dragoumis K, Mikos T, Papadimas J, Bontis J: Expression of estrogen receptors alpha and beta in two uterine mesenchymal tumors after prolonged tamoxifen therapy. Report of two cases. Eur J Gynaecol Oncol; 2004;25(4):530-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASES: The cases of two patients with uterine mesenchymal tumors after prolonged tamoxifen therapy due to breast cancer are presented.
  • The expression of estrogen receptors alpha (ERalpha) and beta (ERbeta) and progesterone receptors (PR) was studied immunohistochemically in both cases.
  • In the first case the tumor was negative for PR, while in the second only 20% of nuclei were PR-positive.
  • [MeSH-major] Carcinosarcoma / chemically induced. Endometrial Neoplasms / chemically induced. Receptors, Estrogen / analysis. Tamoxifen / adverse effects
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Needle. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Chemotherapy, Adjuvant. Estrogen Receptor alpha. Estrogen Receptor beta. Female. Follow-Up Studies. Humans. Immunohistochemistry. Mastectomy / methods. Middle Aged. Neoplasm Staging. Risk Assessment

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15285325.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down






Advertisement